Reference
  1. Welsby IJ, Bennett-Guerrero E, Atwell D, White WD, Newman MF, Smith PK, Mythen MG. The association of complication type with mortality and prolonged stay after cardiac surgery with cardiopulmonary bypass. Anesth Analg 2002;94:1072—8.
  2. Bouza E, Hortal J, Munoz P, Pascau J, Perez MJ, Hiesmayr M, European Study Group on Nosocomial Infections, European Workgroup of Cardiothoracic Intensivists. Postoperativeinfections after major heart surgery and prevention of ventilator-associated neumonia: a one-day European prevalence study (ESGNI-008). J Hosp Infect 2006;64:224—30.
  3. Michalopulos A, Geroulanos S, Rosmarakis ES, Falagas ME. Frequency, characteristics, and redictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg 2006;2:456—60.
  4. De Santo LS, Romano G, Amarelli C, Onorati F, Torella M, Renzulli A,Galdieri N, Cotrufo M. Surgical repair of acute type A aortic dissection: continuous pulmonary perfusion during retrograde cerebral perfusion prevents lung injury in a pilot study. J Thorac Cardiovasc Surg 2003;126:826—31.
  5. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjet R. Guidelines for preventing health-care-associated pneumonia 2003:recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53:1—36.
  6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128—40.
  7. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayahall CG, editor. Hospital epidemiology and infection control. Philadelphia: Lippincot Williams & Wilkins 2004. p. 1659—702.
  8. ATS Board of Directors. In: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388—416.
  9. Magiorakos AP,Srinivasan A,Carey RB, et al. Multidrug-resistant,extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18(3):268-281.
  10. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015;36(1):85–98
  11. Tal-JasperR,KatzDE,Amrami N, etal. Clinical and epidemiologic.al significance of Carbapenem resistance in Acinetobacter baumannii infections. Antimicrob Agents Chemother 2016;60(5):3127–3131.
  12. Gavaldà L, Soriano AM, Cámara J, et al. Control of endemic extensively drug-resistant Acinetobacter baumannii with a cohorting policy and cleaning procedures based on the 1 room, 1wipe approach. Am J Infect Control 2016;44(5):520–524.
  13. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial esistance-treatment options. Semin Respir Crit Care Med 2015;36(1):85–98.
  14. Wisplinghoff H, Paulus T, Lugenheim M, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect 2012;64(3):282-290.
  15. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators.International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302(21):2323–2329.
  16. Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39(2):105–114.
  17. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61(6):1369–1375.
  18. Jaruratanasirikul S, Wongpoowarak W, Aeinlang N, Jullangkoon M. Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother 2013;57(7):3441–3444.
  19. Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 2016;47(4):317–323.
  20. BuissonY, TranVanNhieuG, GinotL, etal. Nosocomial outbreaks due to amikacin-resistant tobramycin-sensitive Acinetobacter species: correlation with amikacin usage. J Hosp Infect 1990;15(1):83–93.
  21. Vincent, Jean-Louis. Nosocomial infection in the ICU. Microbes and Infection 2004;6(11):1003-1007.
  22. Ma CF, Li FQ, Shi LN, Hu YA, Wang Y, Huang M, Kong QQ. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis 2013; 13(1): 337.
  23. Poikonen E, Lyytikäinen O, Anttila VJ, Koivula I, Lumio J,Kotilainen P, Syrjälä H, Ruutu P. Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007. BMC Infect Dis 2010; 10(1): 312.
  24. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11(2): 142–151.
  25. Gavaldà J, Meije Y, Fortún J, Roilides E, Saliba F, Lortholary O, Muñoz P, Grossi P, uenca-Estrella M; ESCMID Study Group for Infections in Compromised Hosts. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 (Suppl 7): 27–48.
  26. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012; 4(165): 163-165.
  27. Gao LY, Yu J, Li RY. Epidemiology of aspergillosis in mainland China. Chin J Mycol (Zhongguo Zhen Jun Xue Za Zhi) 2010; 5(4): 247–251 (in Chinese)